Corvus Pharmaceuticals Inc (CRVS)

01:05 AM

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister

01:05 AM

Apr 09, 2025

Corvus Pharmaceuticals expands board with new director By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

Corvus Pharmaceuticals Appoints Richard A. Van Den Broek To Board Of Directors - marketscreener.com

Apr 09, 2025

Apr 09, 2025

Corvus Pharmaceuticals expands board with new director - Investing.com Australia

Apr 09, 2025

Apr 09, 2025

Corvus Pharmaceuticals Appoints New Director to Board - TipRanks

Apr 09, 2025

Apr 09, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - TradingView

Apr 09, 2025

Apr 09, 2025

Strategic Win: Corvus Pharmaceuticals Lands Former Pharmacyclics Director with ITK Expertise - Stock Titan

Apr 09, 2025

Apr 07, 2025

Corvus Pharmaceuticals’ Earnings Call: Progress Amid Challenges - MSN

Apr 07, 2025

Mar 29, 2025

Research Analysts Issue Forecasts for CRVS FY2028 Earnings - The AM Reporter

Mar 29, 2025

Mar 28, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call Transcript - MSN

Mar 28, 2025

Mar 28, 2025

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha

Mar 28, 2025

Mar 28, 2025

Corvus Pharmaceuticals Stock: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025

Mar 28, 2025

Corvus Pharmaceuticals: Now At Cruising Altitude (NASDAQ:CRVS) - Seeking Alpha

Mar 28, 2025

Mar 27, 2025

Corvus Pharmaceuticals at H.C. Wainwright Conference: Socolitinib’s Promising Trials By Investing.com - Investing.com Canada

Mar 27, 2025

Mar 27, 2025

Institutions along with retail investors who hold considerable shares inCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) come under pressure; lose 24% of holdings value - simplywall.st

Mar 27, 2025

Mar 27, 2025

Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger - Asianet Newsable

Mar 27, 2025

Mar 26, 2025

Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $15 From $14, Maintains Outperform Rating - MarketScreener

Mar 26, 2025

Mar 26, 2025

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 26, 2025

Mar 26, 2025

Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada

Mar 26, 2025

Mar 25, 2025

Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 25, 2025

Mar 25, 2025

Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss By Investing.com - Investing.com Canada

Mar 25, 2025

Mar 25, 2025

Corvus: Q4 Earnings Snapshot - Greenwich Time

Mar 25, 2025

Mar 25, 2025

Earnings call transcript: Corvus Pharmaceuticals Q4 2024 sees wider loss - Investing.com India

Mar 25, 2025

Mar 25, 2025

Corvus Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 25, 2025

CORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly Earnings - Nasdaq

Mar 25, 2025

Mar 23, 2025

CORVUS PHARMACEUTICALS Earnings Preview: Recent $CRVS Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 23, 2025

Mar 21, 2025

Corvus Pharmaceuticals Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

Mar 21, 2025

Mar 21, 2025

Brokerages Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) PT at $12.38 - Armenian Reporter

Mar 21, 2025

Mar 20, 2025

Corvus Pharma Reports Positive Data From Phase 1/1b Study Of Soquelitinib In T Cell Lymphoma - Nasdaq

Mar 20, 2025

Mar 20, 2025

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - The Manila Times

Mar 20, 2025

Mar 20, 2025

New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients - Stock Titan

Mar 20, 2025

Mar 19, 2025

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - The Manila Times

Mar 19, 2025

Mar 19, 2025

Corvus Pharma Reveals Autoimmune Pipeline Strategy at Major HC Wainwright Conference - Stock Titan

Mar 19, 2025

Mar 18, 2025

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - The Manila Times

Mar 18, 2025

Mar 17, 2025

Corvus Pharmaceuticals to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 17, 2025

Mar 17, 2025

Corvus Pharmaceuticals Reveals Q4 Earnings Date: Complete Financial Picture Coming March 25 - StockTitan

Mar 17, 2025

Mar 16, 2025

Corvus Pharmaceuticals (CRVS) to Release Quarterly Earnings on Tuesday - The AM Reporter

Mar 16, 2025

Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) - The Manila Times

Mar 12, 2025

Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for ... - The Bakersfield Californian

Mar 12, 2025

Mar 12, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with - EIN News

Mar 12, 2025

Mar 03, 2025

Corvus Pharmaceuticals: Small Market, Many Competitors, Low Cash Balance (NASDAQ:CRVS) - Seeking Alpha

Mar 03, 2025

Feb 26, 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Buy” from Analysts - Armenian Reporter

Feb 26, 2025